Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A new coronavirus mRNA vaccine targeting humoral and cellular immunity

A vaccine and virus technology, applied in the field of immunity, can solve problems such as immune escape

Active Publication Date: 2022-02-18
SHENZHEN BAY LAB +1
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] However, the current mRNA vaccines mainly have the following two problems: On the one hand, the two new coronavirus mRNA vaccines that have been successfully marketed at present tend to induce neutralizing antibodies to exert a protective immune response, and have not yet explored the targeted induction of T Cellular Immune Responses Develop Specific Design
On the other hand, some dominant variants produced by the continuous mutation of the new coronavirus during the epidemic include Alpha variant (B.1.1.7), Beta variant (B.1.351), Gamma variant (P.1), Delta variant (B. .1.617.2), etc., for antibodies induced by current mRNA vaccines, severe immune escape may occur

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A new coronavirus mRNA vaccine targeting humoral and cellular immunity
  • A new coronavirus mRNA vaccine targeting humoral and cellular immunity
  • A new coronavirus mRNA vaccine targeting humoral and cellular immunity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0068] This embodiment provides a combination of antigen expression vectors for the novel coronavirus mRNA vaccine. The combination of antigen expression vectors includes three antigen expression vectors, namely pCA-RBD-SA, pCA-Ub-rMN and pCA-Ub-NSPs.

[0069] These antigen expression vectors are respectively referred to Figure 1~3 , wherein, there is an antigen coding region on the pCA-RBD-SA plasmid, and the antigen coding region includes the sequence of coding tPA signal peptide and the sequence of coding RBD-SA fragment connected in sequence, at the 3′ of the sequence of coding RBD-SA fragment A sequence encoding a Flag tag and a stop codon were also inserted at the end (the Flag sequence and stop codon are not shown in the figure). The T7 promoter, 5' untranslated region (5'-UTR), 3' untranslated region (3'-UTR), and polyadenylic acid (polyA) are also connected upstream and downstream of the antigen coding region, respectively.

[0070] There is an antigen coding regio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a new coronavirus mRNA vaccine targeting to stimulate humoral immunity and cellular immunity. A first aspect of the present application provides an isolated combination of DNA molecules comprising a first DNA molecule and at least one of a second DNA molecule and a third DNA molecule. Through the combination of the first DNA molecule and the second DNA molecule and / or the third DNA molecule, use the mRNA finally synthesized by the first DNA molecule to induce a high titer of cross-neutralizing antibodies, and use the second DNA molecule and / or the third DNA The mRNA synthesized at the end of the molecule induces new coronavirus-specific cytotoxic T lymphocytes, thereby efficiently activating relatively independent humoral immune responses and cellular immune responses at the same time, and responding to the breakthrough caused by the mutant strains of the new coronavirus during the epidemic transmission sexual infection.

Description

technical field [0001] This application relates to the field of immune technology, in particular to a novel coronavirus mRNA vaccine that targets and stimulates humoral immunity and cellular immunity. Background technique [0002] Compared with other traditional vaccines, mRNA vaccines have the advantages of short research and development cycle and relatively low research and development costs. At the same time, their physical and chemical properties such as solubility are suitable for drug research and development, and they have high safety; The risk of sexual viral infection has become a hot spot in vaccine research and development. In the design of the target antigen gene, different antigen sequences are selected for construction according to the type of protective immune response induced by the target. An ideal vaccine design can effectively induce pathogen-specific humoral and cellular immune responses. [0003] However, the current mRNA vaccines mainly have the follow...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/62C12N15/85A61K39/215A61K9/51A61P31/14
CPCC07K14/005C12N15/85A61K39/12A61K9/5107A61P31/14C12N2770/20022C07K2319/02C07K2319/95C07K2319/40C12N2800/107C12N2770/20034A61K2039/53
Inventor 程功太万博冯胜勇童良琴庞慕加蔡珠明
Owner SHENZHEN BAY LAB
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com